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doi:10.1016/j.ejvs.2011.07.027Abstract Objective: Arterial stiffness is a significant determinant of cardiovascular risk and
is related to vascular calcification. Vitamin D may regulate arterial calcification and has been
associated with cardiovascular survival benefits. However, data about the relationship
between arterial stiffness, aortic calcification and vitamin D levels in patients with peripheral
arterial disease (PAD) and in healthy subjects are limited. We examined the potential associ-
ation between aortic calcification, arterial stiffness and vitamin D levels in patients with symp-
tomatic PAD and in healthy individuals.
Methods: We studied 78 men with PAD (aged 63  7 years) and 74 healthy men (aged 61  10
years). Aortic pulse wave velocity (aPWV) was determined by applanation tonometry using the
Sphygmocor device. Aortic calcification score (ACS) was quantified by computed tomography.
Serum 25-hydroxyvitamin D (25(OH)D) levels were measured using a radioimmune assay.
Results: ACS (4.9(2.3e8.9) vs. 0.2(0.03e1.6) (cm3); p < 0.01), aPWV (9.8  2.4 vs. 8.2  1.6
(m s1); p < 0.01) and 25(OH)D (15.1  5.4 vs. 19.0  5.9 (ng ml1); p < 0.01) were different
in the patients compared with the controls. In multivariate analysis, ACS was independently
determined by 25(OH)D, aPWV, calcium and age in patients with PAD (R2 Z 0.49; p < 0.001)
and by 25(OH)D, aPWV, cholesterol/high-density lipoprotein (HDL) and age in the control groupDepartment of Biochemistry, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Tel.: þ372
iinikum.ee (M. Zagura).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
690 M. Zagura et al.(R2 Z 0.55; p < 0.001). Increased aPWV and lower levels of 25(OH)D were associated with
decreased ankleebrachial pressure index (p Z 0.03).
Conclusion: These results indicate that calcification of the aorta is independently associated
with aortic stiffness and serum 25(OH)D level in patients with PAD and in healthy subjects.
Aortic stiffness and abnormal vitamin D level may contribute to vascular calcification and
are related to higher severity grade of atherosclerotic disease.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Arterial calcification is an independent predictor of
vascular morbidity and mortality in the general population1
and is also a marker of sub-clinical atherosclerotic disease.2
There is evidence that vascular calcification might
contribute to the increase in arterial stiffness3 and vice
versa.4 In chronic kidney disease, a strong cross-sectional
relationship has been demonstrated between arterial
calcifications and stiffness of the aorta.5,6 Aortic pulse
wave velocity (aPWV), the current gold-standard measure
of aortic stiffness,7 is related to aortic calcification in
patients with peripheral arterial disease (PAD),8 isolated
systolic hypertension and in the general population.3
Vitamin D is closely related to vascular calcification.
Serum 25-hydroxyvitamin D (25(OH)D) correlates with
calcification of the iliac and femoral arteries.9 Injection of
activated vitamin D is associated with better survival in
haemodialysis patients.10 Moreover, recent data indicate
that 1,25-dihydroxyvitamin D (1,25(OH)2D) reduces pro-
inflammatory cytokine secretion11 and down-regulates the
renineangiotensin system (RAS).12
Calcified atherosclerotic arteries,13 increased arterial
stiffness14 and vitamin D deficiency15 might influence the
clinical course of PAD. However, data about the association
between these parameters in patients with PAD are limited.
The aim of this study was to evaluate the relationship
between aortic calcification, arterial stiffness and 25(OH)D
in patients with symptomatic PAD and in clinically healthy
men. In addition, we examined the association of 25(OH)D
with peripheral and central blood pressure (BP).MethodsSubjects
A total of 78 patients with documented PAD participated in
this study. The patients, fulfilling the inclusion criteria,
were recruited from the Department of Vascular Surgery,
University of Tartu. The diagnosis of PAD required (1) clin-
ical symptoms of PAD, (2) ankleebrachial pressure index
(ABPI) <0.9 and (3) significant stenoses or occlusions of
arteries confirmed by angiography. The stage of the disease
was determined according to the Fontaine classification:
stage IIZ intermittent claudication, stage IIIZ leg pain at
rest and stage IV Z tissue loss due to ischaemic ulcer or
gangrene. The exclusion criteria were myocardial infarc-
tion, coronary revascularisation, or cerebrovascular events
during the previous 6 months, earlier revascularisation
procedures at the lower limb, upper limb occlusive arterial
disease, cardiac arrhythmias or valve pathologies, diabetesmellitus, malignancies, renal failure (estimated glomerular
filtration rate (eGFR) <60 ml min1 1.73 m2), known
inflammatory conditions or use of vitamin D supplements. In
total, 30 (38.5%) patients with hypertension and 12 (15.4%)
patients with coronary artery disease as the co-morbidity
were included in the study.
A total of 74 clinically healthy men were recruited by
a family physician and by a specialist of sports medicine. To
be eligible as controls, the subjects had to be free from any
acute or chronic inflammatory disease, coronary artery
disease, cardiac arrhythmias or valve pathologies, cerebral
or peripheral atherosclerotic disease, diabetes mellitus,
malignancies, renal failure (eGFR <60 ml1 min1 1.73 m2)
or use of vitamin D supplements. The control subjects did
not use any medications on a regular basis. All participants
provided written informed consent and the study was
approved by the Ethics Committee of the University of Tartu.
Haemodynamic measurements
Brachial BP and heart rate were measured supine in the left
arm using an automated digital oscillometric BP monitor
(OMRON M4-I; Omron Healthcare Europe, Hoofdorp, the
Netherlands). Radial artery waveforms were recorded with
a high-fidelity micromanometer (SPT-301B; Millar Instru-
ments, Houston, TX, USA) from the wrist of the left hand.
Pulse wave analysis (SCOR Px, 7.0; AtCor Medical, Sydney,
Australia) was used to generate radial artery waveforms. A
generalised validated transfer function was then used to
generate a corresponding central (ascending aortic) wave-
form.16 Aortic augmentation index (AIx) was measured as
the height of the late systolic peak divided by aortic pulse
pressure. The AIx was adjusted to a heart rate of
75 beats min1 (AIx@75), as calculated by the Sphygmocor
software.16 Mean arterial pressure (MAP) was calculated
from the integration of the radial artery waveform. PWV
was determined by the foot-to-foot method, using the
Sphygmocor device.16 Electrocardiogram-gated femoral and
carotid artery waveforms were sequentially recorded to
measure aPWV. Brachial PWV (bPWV) was determined from
carotid and radial waveforms.16 Haemodynamic measure-
ments were performed by two experienced investigators.
All measurements were made in duplicate, and mean values
were used in subsequent analysis. The within- and between-
observer measurement reproducibility values for aPWV and
AIx were consistent with previously published data.16
The ABPI was measured using the Bidirectional Doppler
MD 6 (D.E, Hokanson, Bellevue, WA, USA). Systolic BP was
measured bilaterally over the brachial, tibialis posterior
and dorsalis pedis arteries. The higher systolic BP of the
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calculation of the ABPI.17 Two readings of the ABPI were
performed and the mean was calculated. The lower ABPI of
the two legs was included in statistical analysis.
Computed tomography
Computed tomography (CT) scans of the aorta were per-
formed in 52 patients with PAD and in 60 clinically healthy
men. All study participants were informed about the
purpose, methods, radiation dose and risks associated with
radiation exposure. We could not perform CT scans in all of
the subjects due to the lack of consent and considering also
the fact that some patients had several CT scans in their
previous medical history. The entire aorta (from the aortic
valve to bifurcation) was visualised by obtaining 5-mm-
thick slices through the thorax, abdomen and pelvis with
non-contrast helical CT (GE LightSpeed 16, General Elec-
trical Medical Systems, Milwaukee, WI, USA; total dose:
<8 mSv) (Fig. 1). Analysis was conducted using a Siemens
Syngo Multimodality Workplace workstation. Aortic calcifi-
cation score (ACS) was measured by an independent
observer. The degree of calcification was determined by
the volume scoring method. The number of voxels of 130 or
greater Hounsfield units within the wall of the aorta yielded
a calcification score in cubic centimetres. This is a vali-
dated and accurate technique that compares favourably
with electron beam CT.18
Laboratory analysis
Blood was collected after an overnight fast on the morning
of CT assessment. Serum (25(OH)D) level was measured
using a radioimmune assay (25-Hydroxyvitamin D, 125I Ria
Kit, DiaSorin Corporation, Minnesota, USA). The plasma
level of soluble intercellular adhesion molecule-1 (sICAM)
was measured by an enzyme-linked immunosorbent assay
(ELISA) using a commercially available kit (Human soluble
intercellular adhesion molecule-1 Immunoassay; R&D
Systems; Minneapolis, MN, USA). Serum levels of interleukin
(IL)-6 were determined using a chemiluminescent immu-
noassay (Immulite; Diagnostic Products Corporation, Los
Angeles, CA, USA). Plasma cholesterol, triglyceride, high-
(HDL) and low-density (LDL) lipoprotein, glucose, creati-
nine, high-sensitivity C-reactive protein (hsCRP) and
calcium concentrations were measured by standard labo-
ratory methods using certified assays in the local clinical
laboratory. The eGFR was determined using the Modifica-
tion of Diet in Renal Disease formula, equation MDRD 1.19Figure 1 A cross-section of the abdomen illustrating (A) non-cAll determination procedures were performed in accor-
dance with the manufacturer’s recommendation.
Protocol
The subjects were studied in the morning between 8 AM
and 10 AM. They had abstained from smoking and intake of
caffeine-containing food and beverages for the previous
12 h. Studies were conducted in a quiet temperature-
controlled room. First, height and weight were assessed
and, next, body mass index was calculated. After the
subjects had spent 15 min resting in the supine position,
brachial BP and radial artery waveforms were recorded.
Further, aPWV, bPWV, AIx@75 and ABPI were measured.
Twenty millilitres of blood were drawn from the antecubital
fossa into plain tubes. The subjects then underwent CT.
Statistical analysis
Statistical analysis was performed using the software STA-
TISTICA (version 9.1 for Windows; StatSoft, Tulsa, Okla-
homa, USA). All variables included in the analysis were
verified for normality using the KolmogoroveSmirnov test.
Because distribution of ACS was significantly skewed, the
calcification scores were log10-transformed for subsequent
analyses. As there was significant difference in BP between
the study groups, aPWV and bPWV have been adjusted for
MAP before analysis. The results are presented as
means  standard deviations for normally distributed data.
Variables with a non-normal distribution are presented as
medians and interquartile ranges. Comparisons between
the patients and the controls were performed using the
unpaired t-tests for parametric data and the Man-
neWhitney U-tests for non-parametrically distributed data.
Comparison between multiple unpaired groups was per-
formed using the one-way analysis of variance (ANOVA).
Multiple regression analysis was performed to investigate
the independent determinants of ACS. Values of p < 0.05
were considered statistically significant.
Results
Participant characteristics
The characteristics of the study population are summarised
in Table 1. The patients with PAD had higher ACS, aPWV and
peripheral and central systolic BP, compared with the
controls. By contrast, 25(OH)D levels were significantlyalcified aortic wall, (B) calcification within the aortic wall.
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inflammation, such as hsCRP, sICAM and IL-6, were higher in
the patient group. There were no differences between the
groups regarding bPWV, eGFR, plasma glucose and HDLTable 1 Baseline characteristics of the participants
(mean  s.d.).
Parameter PAD patients
(n Z 78)
Controls
(n Z 74)
P value
Age (years) 63  7 61  10 0.1
BMI (kg/m2) 25.4  3.8 27.0  3.5 <0.01
ABPI 0.43  0.3 1.2  0.1 <0.01
ACS (cm3)a 4.9 (2.3e8.9) 0.2 (0.03e1.6) <0.01
Heart rate
(beats/min)
66.6  12.1 58.9  9.2 <0.01
MAP (mmHg) 103.9  13.8 97.0  11.2 <0.01
PSBP (mmHg) 148.4  20.8 131.9  15.2 <0.01
PDBP (mmHg) 81.3  10.4 77.9  8.6 0.03
PPP (mmHg) 66.1  14.6 54.1  10.8 <0.01
CSBP (mmHg) 135.7  19.2 122.3  16.3 <0.01
CDBP (mmHg) 82.3  10.9 79.3  9.3 0.07
CPP (mmHg) 53.4  12.9 43.0  11.2 <0.01
aPWV (m/s)b 9.8  2.4 8.2  1.6 <0.01
bPWV (m/s)b 8.7  1.3 8.8  1.2 0.73
AIx@75 (%) 28.2  8.0 17.1  9.9 <0.01
Glucose (mmol/L) 5.6  1.0 5.4  0.5 0.13
Total cholesterol
(mmol/L)
5.9  1.2 5.3  1.1 <0.01
LDL (mmol/L) 4.2  1.1 3.7  1.1 <0.01
HDL (mmol/L) 1.3  0.4 1.3  0.3 0.49
Triglycerides
(mmol/L)
1.7  0.7 1.1  0.7 <0.01
eGFR
(mL/min/1.73 m2)
99.7  25.8 95.1  20.7 0.2
hsCRP (mg/L)a 4.1 (1.4e8.5) 0.9 (0.5e1.6) <0.01
Calcium (mmol/L) 2.4  0.2 2.2  0.2 <0.01
25(OH)D (ng/mL) 15.1  5.4 19.0  5.9 <0.01
sICAM (ng/mL) 265.5  65.5 174.9  36.3 <0.01
IL-6 (ng/L)a 4.0 (2.1e7.0) 2.0 (1.9e3.0) <0.01
Current
smoking, n (%)
78 (100) 18 (24) <0.01
Framingham
risk score (%)c
ND 11.4  7.3 ND
PAD, peripheral arterial disease; BMI, body mass index; ABPI,
ankleebrachial pressure index; ASC, aortic calcification score;
MAP, mean arterial pressure; PSBP, peripheral systolic blood
pressure; PSBP, peripheral diastolic blood pressure; PPP,
peripheral pulse pressure; CSBP, central systolic blood pressure;
CDBP, central diastolic blood pressure; CPP, central pulse
pressure; aPWV, aortic pulse wave velocity; bPWV, brachial
pulse wave velocity; AIx@75, augmentation index corrected for
a heart rate of 75 beats per minute; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein; eGFR, estimated glomer-
ular filtration rate; hsCRP, high-sensitivity C-reactive protein;
25(OH)D, 25-hydroxyvitamin D; sICAM, soluble intercellular
adhesion molecule; IL-6, interleukin-6.
a Indicates medians and interquartile ranges.
b aPWV and bPWV have been adjusted for MAP.
c Risk was not assessed for PAD patients since they had
established vascular disease, which indicates high cardiovas-
cular risk.concentrations. Differences in the use of medication were
observed between the study groups: 31 (39.7%) patients
were on pentoxifylline treatment, 20 (25.6%) patients
received aspirin, 9 (11.5%) patients were on statin therapy,
15 (19.2%) patients received angiotensin-converting
enzyme inhibitors, 14 (17.9%) patients were on calcium
channel blocker treatment, 7 (9%) patients received
angiotensin-receptor blockers, 5 (6.4%) patients were on
beta-blocker therapy and 3 (3.8%) patients received
diuretics, whereas the control subjects did not use any
medications on a regular basis.
Relationship between aortic calcification, arterial
stiffness and vitamin D
Log-ACS was significantly correlated with aPWV in PAD
patients (rZ 0.28; pZ 0.03) and in the controls (rZ 0.57;
p < 0.001) (Fig. 2(A)). The log-ACS showed positive corre-
lation with 25(OH)D levels in PAD patients (r Z 0.33;
p Z 0.01) and negative correlation in the control subjects
(r Z 0.47; p < 0.001) (Fig. 2(A)). Log-ACS was positively
correlated with log-hsCRP (rZ 0.29, pZ 0.03) and log-IL-6
(r Z 0.28, p Z 0.03) only in PAD patients. Multivariate
analysis revealed that log-ACS was independently associ-
ated with 25(OH)D, aPWV, eGFR, calcium and age
(R2 Z 0.49; p < 0.001) in PAD patients and with 25(OH)D,
aPWV, cholesterol/HDL ratio and age (R2Z 0.55; p < 0.001)
in the clinically healthy men (Table 2). Adjustment for
seasonal variation of vitamin D, anti-hypertensive and
vasodilator treatment, systolic, diastolic and pulse pres-
sure, glucose, LDL, triglycerides, height and weight did not
alter the associations (data not shown). Log-ACS correlated
with both peripheral and central pulse pressure in PAD
patients (r Z 0.31, p Z 0.01 and r Z 0.29, p Z 0.02,
respectively) and in the control subjects (r Z 0.37,
p Z 0.004 and r Z 0.46, p < 0.001, respectively). It was
significantly correlated with AIx@75 (r Z 0.48, p < 0.001)
only in the control subjects. However, this correlation was
not significant after adjustment for confounders.
Vitamin D levels were negatively correlated with
peripheral systolic blood pressure (PSBP) (r Z 0.3,
p Z 0.01), peripheral diastolic blood pressure (PDBP)
(r Z 0.29, p Z 0.01), central systolic blood pressure
(CSBP) (r Z e-0.3, p Z 0.01), central diastolic blood
pressure (CDBP) (r Z 0.28, p Z 0.02), peripheral pulse
pressure (PPP) (r Z 0.24, p Z 0.04) and MAP (r Z 0.3,
p Z 0.01) only in PAD patients. Vitamin D correlated
significantly with AIx@75 in the controls (r Z 0.26;
p Z 0.03). There was a trend towards correlation between
25(OH)D concentrations and aPWV (r Z 0.23, p Z 0.057)
only in the control subjects.
Determinants of severity grade of PAD
We tested the hypothesis about whether increased arterial
stiffness and decreased vitamin D levels are associated with
more advanced atherosclerotic disease. In univariate
analysis, there was borderline correlation between ABPI
and 25(OH)D (r Z 0.26, p Z 0.051). We evaluated the
relationship between ABPI and the composite measure of
aPWV and 25(OH)D. Patients were divided into three
Figure 2 Correlation between aPWV and log-ACS for the
patients (r Z 0.28, p Z 0.03) and for the control subjects
(r Z 0.57, p < 0.001) (A). Correlation between 25(OH)D and
log-ACS for the patients (r Z 0.33, p Z 0.01) and for the
control subjects (r Z 0.47, p < 0.001) (B). The aPWV has
been adjusted for MAP. Filled dots represent patients; empty
dots represent controls. Continuous line represents regression
line through the patient data; interrupted line represents
regression line through the control data.
Vascular Function and Vitamin D 693groups, according to aPWV and 25(OH)D values. The first
group comprised patients with aPWV below the median
(9.7 m s1) and 25(OH)D above the median (15.2 ng ml1)
(n Z 12). The second group consisted of patients with
either aPWV >9.7 m s1 or 25(OH)D  15.2 ng ml1
(n Z 35). Patients in the third group had aPWV >9.7 m s1
and 25(OH)D  15.2 ng ml1 (n Z 19). There was a signifi-
cant inverse association between ABPI and the composite
measure of aPWV and 25(OH)D (pZ 0.03). To illustrate this
association, we divided PAD patients into tertiles according
to aPWV and 25(OH)D values. As shown in Fig. 3, higher
aPWV and lower 25(OH)D levels were related to lower ABPI.
Discussion
The principal finding of the present study is that increased
aortic stiffness and abnormal vitamin D levels areindependently associated with the extent of aortic calcifi-
cation in patients with symptomatic PAD and in clinically
healthy subjects. Furthermore, 25(OH)D and aPWV were
related to the severity grade of atherosclerotic disease. To
the best of our knowledge, this is the first study that has
demonstrated relationship between aortic stiffness, calci-
fication of the aorta and vitamin D levels in patients with
angiographically proven PAD.
We have demonstrated that PAD is associated with aortic
calcification, which is consistent with the results of
previous studies. In subjects with type 2 diabetes, aortic
calcification was higher in the patients who developed
intermittent claudication than in those who were symptom-
free during follow-up.13 Our finding that aPWV is elevated
in patients with PAD is supported by the results of a large
cross-sectional study.20
In our study, serum 25(OH)D was significantly lower in
the patient group as compared with the controls. Similarly,
the results of a large epidemiological study indicate that
there is strong association between lower levels of 25(OH)D
levels and prevalence of PAD.15 It has been hypothesised
that patients with PAD may be less mobile and receive
therefore less sun exposure.15
The association between arterial stiffness and vascular
calcification has been demonstrated in several cross-
sectional studies. In dialysis patients, strong relationship
has been demonstrated between abdominal aortic calcifi-
cation and stiffness of the aorta.6 Moreover, aortic calcifi-
cation was positively correlated with aPWV and peripheral
pulse pressure in healthy individuals.3,8 We demonstrated
association between aPWV and ACS both in patients with
PAD and in clinically healthy men. These associations
remained significant after adjustment for several cardio-
vascular risk factors. Central pulse pressure, which is
a well-known measure of aortic stiffness,21 correlated with
aortic calcification in both study groups. These findings
suggest that aortic calcification and its stiffening might
influence development of PAD and indicate also the pres-
ence of sub-clinical atherosclerosis in healthy subjects. By
contrast, there was no relationship between ACS and bPWV
in the patients with PAD. One potential explanation for the
lack of association between ACS and bPWV is that aortic
calcification is specifically related to the stiffness of the
aorta rather than the brachial artery.
There are a number of possible explanations for the
relationship between aortic stiffness and vascular calcifi-
cation. It has been hypothesised that increased arterial
stiffness could lead to vessel wall damage and calcifica-
tion.5 Alternatively, vascular calcification could lead to
stiffening of the arteries.3,6 Finally, it might be that both
vascular calcification2 and arterial stiffness22 are the
consequences of age-related degenerative processes in the
vasculature.
The effects of vitamin D on vascular calcification appear
to follow a biphasic pattern, with both excess and defi-
ciency promoting its development.23 Low levels of 25(OH)D
are associated with extensive vascular calcification9 and
injection of activated vitamin D increases survival in
patients with end-stage renal disease.10 On the other hand,
treatment with vitamin D increases aortic calcification in
animal models.24 In our study, serum levels of 25(OH)D
correlated positively with ACS in PAD patients and
Table 2 Multiple regression analysis for PAD patients and
the control subjects with the logarithm of aortic calcifica-
tion score as the dependent variable.
Regression
coefficient
Standard
error
P value
Patientsa
25(OH)D (ng/mL) 0.04 0.01 0.008
Age (years) 0.04 0.01 0.01
aPWV (m/s)c 0.09 0.04 0.02
Calcium (mmol/L) 1.23 0.53 0.02
eGFR (mL/min/1.73 m2) 0.008 0.003 0.03
sICAM (ng/mL) 0.002 0.001 0.13
Controlsb
25(OH)D (ng/mL) 0.05 0.02 0.003
aPWV (m/s)c 0.19 0.07 0.01
Cholesterol/HDL 0.15 0.07 0.03
Age (years) 0.02 0.01 0.03
25(OH)D, 25-hydroxyvitamin D; aPWV, aortic pulse wave
velocity; sICAM, soluble intercellular adhesion molecule; eGFR,
estimated glomerular filtration rate; HDL, high-density lipo-
protein; MAP, mean arterial pressure.
a R2 value Z 0.49; p < 0.001; n Z 46.
b R2 value Z 0.55; p < 0.001; n Z 55.
c aPWV has been adjusted for MAP.
694 M. Zagura et al.negatively in the control subjects. It might be that different
localisations of calcium deposits in the aortic wall are
responsible for different patterns of correlation between
aortic calcification and vitamin D seen among the study
groups. Previous studies indicate that, in patients with
atherosclerosis, mostly intimal calcification is seen.6 By
contrast, medial calcification is associated with diabetes
mellitus, end-stage renal disease and ageing.6 Based on
these observations, we hypothesised that a mixture of
intimal and medial calcification occurred in PAD patients,
whereas age-related medial calcification was predominant
in the healthy men. Thus, serum 25(OH)D levels might be
differently associated with adverse morphologic changes in
the aorta, depending on the clinical condition of subjects.Figure 3 Relationship between ABPI and the tertiles of aPWV
and 25(OH)D in PAD patients. The aPWV has been adjusted for
MAP. ABPI, ankleebrachial pressure index; aPWV, aortic pulse
wave velocity; 25(OH)D, 25-hydroxyvitamin D; MAP, mean
arterial pressure.Lower circulating 25(OH)D levels are associated with
higher prevalence of hypertension.25 Previous studies indi-
cate that vitamin D may modulate vascular smooth muscle
tone26 and may also act as an endogenous inhibitor of RAS12
by influencing the concentration of calcium in juxtaglo-
merular cells. Similarly, we have shown that 25(OH)D levels
were negatively correlated with central and peripheral BP
in patients with atherosclerosis. Our results support the
role of vitamin D in modulation of BP.
The ABPI has been widely adopted for confirmation of
the clinical diagnosis of PAD and for determining its severity
grade. Having a low ABPI value is an independent risk factor
for all-cause and cardiovascular mortality in patients with
PAD.27 We have shown that increased aPWV and lower
25(OH)D levels are associated with lower ABPI values. This
finding suggests that aPWV and vitamin D status might
provide additional information about severity grade of PAD.
There are potential limitations to the present study.
First, the study was cross sectional. As in any cross-
sectional study, the established associations do not indi-
cate cause-and-effect relationship. Second, we studied
only men to avoid the complicating effects of endogenous
hormones, considering also that patients with PAD are
predominantly men. This makes it difficult to extrapolate
our results to women. Third, a substantial proportion of PAD
patients used anti-hypertensive, vasodilating and anti-
aggregant medications, which might have affected the
results of haemodynamic measurements. Fourth, the
patients with PAD were older than the control subjects.
However, we performed statistical analysis separately in
either of the study groups. Moreover, the proportion of
smokers was significantly higher in the patient group.
Finally, as the study groups were relatively small, our
findings should be verified in larger studies.
In conclusion, the present study demonstrated that
serum 25(OH)D and aortic stiffness are independently
associated with aortic calcification in patients with PAD and
in healthy individuals. Furthermore, increased aortic stiff-
ness and lower levels of 25(OH)D are related to higher
severity grade of PAD. In patients with atherosclerosis,
vitamin D was negatively correlated with peripheral and
central BP. Our results suggest that vascular calcification,
arterial stiffening and vitamin D may have an important
role in the pathogenesis of atherosclerosis. Potentially,
assessment of vitamin D status, arterial stiffness and aortic
calcification may be used for the risk stratification and
optimisation of treatment in patients with atherosclerosis.
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